Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K3BR
|
|||
| Drug Name |
PMID25656651-Compound-26b
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H15ClN6
|
|||
| Canonical SMILES |
C1=CC2=C(NC3=C(C=CN=C3)C4=CN=C(N=C24)NCC5=CC=C(C=C5)Cl)N=C1
|
|||
| InChI |
1S/C21H15ClN6/c22-14-5-3-13(4-6-14)10-25-21-26-11-17-15-7-9-23-12-18(15)27-20-16(19(17)28-21)2-1-8-24-20/h1-9,11-12H,10H2,(H,24,27)(H,25,26,28)
|
|||
| InChIKey |
PBJUHSSYAPBPIB-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.